ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets | Business
LONDON--(BUSINESS WIRE)--Jul 28, 2022--ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, ...
